{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:38:17Z","timestamp":1790678297435,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41386-018-0072-2","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T11:44:14Z","timestamp":1524051854000},"page":"1706-1711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia"],"prefix":"10.1038","volume":"43","author":[{"given":"Joshua","family":"Chiappelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M.","family":"Notarangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Andrea","family":"Wijtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian A. R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pocivavsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Wisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kochunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schwarcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Elliot","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"72_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nn1207","volume":"7","author":"JP Johansen","year":"2004","unstructured":"Johansen JP, Fields HL. Glutamatergic activation of anterior cingulate cortex produces an aversive teaching signal. Nat Neurosci. 2004;7:398\u2013403.","journal-title":"Nat Neurosci"},{"key":"72_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nrn2994","volume":"12","author":"AJ Shackman","year":"2011","unstructured":"Shackman AJ, Salomons TV, Slagter HA, Fox AS, Winter JJ, Davidson RJ. The integration of negative affect, pain and cognitive control in the cingulate cortex. Nat Rev Neurosci. 2011;12:154\u201367.","journal-title":"Nat Rev Neurosci"},{"key":"72_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1515\/REVNEURO.2008.19.4-5.227","volume":"19","author":"S Geisler","year":"2008","unstructured":"Geisler S, Wise RA. Functional implications of glutamatergic projections to the ventral tegmental area. Rev Neurosci. 2008;19:227\u201344.","journal-title":"Rev Neurosci"},{"key":"72_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/mp.2016.87","volume":"22","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Dedic N, P\u00f6hlmann ML, H\u00e4usl A, Karst H, Engelhardt C, et al. Forebrain glutamatergic, but not GABAergic, neurons mediate anxiogenic effects of the glucocorticoid receptor. Mol Psychiatry. 2017;22:466\u201375.","journal-title":"Mol Psychiatry"},{"key":"72_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1126\/science.1202107","volume":"333","author":"D Refojo","year":"2011","unstructured":"Refojo D, Schweizer M, Kuehne C, Ehrenberg S, Thoeringer C, Vogl AM, et al. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science. 2011;333:1903\u20137.","journal-title":"Science"},{"key":"72_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cercor\/bhx205","volume":"11","author":"J Wei","year":"2017","unstructured":"Wei J, Zhong P, Qin L, Tan T, Yan Z. Chemicogenetic restoration of the prefrontal cortex to amygdala pathway ameliorates stress-induced deficits. Cereb Cortex. 2017;11:1\u201311.","journal-title":"Cereb Cortex"},{"key":"72_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/sj.mp.4001551","volume":"9","author":"DC Javitt","year":"2004","unstructured":"Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9:984\u201397.","journal-title":"Mol Psychiatry"},{"key":"72_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2174\/1568007024606212","volume":"1","author":"JT Coyle","year":"2002","unstructured":"Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord. 2002;1:183\u20139.","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"72_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cpr.2006.09.005","volume":"27","author":"I Myin-Germeys","year":"2007","unstructured":"Myin-Germeys I, van Os J. Stress-reactivity in psychosis: evidence for an affective pathway to psychosis. Clin Psychol Rev. 2007;27:409\u201324.","journal-title":"Clin Psychol Rev"},{"key":"72_CR10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/schbul\/sbn002","volume":"35","author":"NM Docherty","year":"2009","unstructured":"Docherty NM, St Hilaire A, Aakre JM, Seghers JP. Life events and high-trait reactivity together predict psychotic symptom increases in schizophrenia. Schizophr Bull. 2009;35:638\u201345.","journal-title":"Schizophr Bull"},{"key":"72_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465\u201377.","journal-title":"Nat Rev Neurosci"},{"key":"72_CR12","doi-asserted-by":"crossref","unstructured":"Schwarcz R. Kynurenines and glutamate: multiple links and therapeutic implications. In: Schwarcz R, editor. Neuropsychopharmacology: a tribute to Joseph T. Coyle. Advances in Pharmacology, vol. 76. Cambridge, MA: Academic Press; 2016. p. 13\u201337","DOI":"10.1016\/bs.apha.2016.01.005"},{"key":"72_CR13","doi-asserted-by":"publisher","first-page":"10592","DOI":"10.1523\/JNEUROSCI.1107-14.2014","volume":"34","author":"R Kozak","year":"2014","unstructured":"Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, et al. Reduction of brain kynurenic acid improves cognitive function. J Neurosci. 2014;34:10592\u2013602.","journal-title":"J Neurosci"},{"key":"72_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/schbul\/sbq002","volume":"36","author":"I Wonodi","year":"2010","unstructured":"Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull. 2010;36:211\u20138.","journal-title":"Schizophr Bull"},{"key":"72_CR15","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/schbul\/sbt157","volume":"40","author":"HQ Wu","year":"2014","unstructured":"Wu HQ, Okuyama M, Kajii Y, Pocivavsek A, Bruno JP, Schwarcz R. Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor. Schizophr Bull. 2014;40:S152\u20138.","journal-title":"Schizophr Bull"},{"key":"72_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/schbul\/sbq112","volume":"37","author":"KV Sathyasaikumar","year":"2011","unstructured":"Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2011;37:1147\u201356.","journal-title":"Schizophr Bull"},{"key":"72_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0006-3223(01)01078-2","volume":"50","author":"R Schwarcz","year":"2001","unstructured":"Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001;50:521\u201330.","journal-title":"Biol Psychiatry"},{"key":"72_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/schbul\/sbq086","volume":"38","author":"KR Linderholm","year":"2012","unstructured":"Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012;38:426\u201332.","journal-title":"Schizophr Bull"},{"key":"72_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.schres.2005.07.013","volume":"80","author":"LK Nilsson","year":"2005","unstructured":"Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstr\u00f6m LH, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005;80:315\u201322.","journal-title":"Schizophr Res"},{"key":"72_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jamapsychiatry.2014.243","volume":"71","author":"J Chiappelli","year":"2014","unstructured":"Chiappelli J, Pocivavsek A, Nugent KL, Notarangelo FM, Kochunov P, Rowland LM, et al. Stress induced kynurenic acid as a potential biomarker for schizophrenia patients with distress intolerance. JAMA Psychiatry. 2014;71:761\u20138.","journal-title":"JAMA Psychiatry"},{"key":"72_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/mp.2010.50","volume":"16","author":"EY Yuen","year":"2011","unstructured":"Yuen EY, Liu W, Karatsoreos IN, Ren Y, Feng J, McEwen BS, et al. Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory. Mol Psychiatry. 2011;16:156\u201370.","journal-title":"Mol Psychiatry"},{"key":"72_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.neubiorev.2015.01.007","volume":"51","author":"SA Wijtenburg","year":"2015","unstructured":"Wijtenburg SA, Yang S, Fischer BA, Rowland LM. In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia. Neurosci Biobehav Rev. 2015;51:276\u201395.","journal-title":"Neurosci Biobehav Rev"},{"key":"72_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/schbul\/sbq059","volume":"37","author":"B Kirkpatrick","year":"2011","unstructured":"Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37:300\u20135. 2011","journal-title":"Schizophr Bull"},{"key":"72_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","volume":"68","author":"RS Keefe","year":"2004","unstructured":"Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68:283\u201397.","journal-title":"Schizophr Res"},{"key":"72_CR25","volume-title":"Wechsler adult intelligence scale \u2013 third edition (WAIS-III)","author":"D Wechsler","year":"1997","unstructured":"Wechsler D. Wechsler adult intelligence scale \u2013 third edition (WAIS-III). San Antonio, TX: Harcourt Assessment; 1997."},{"key":"72_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.biopsych.2008.04.005","volume":"64","author":"D Dickinson","year":"2008","unstructured":"Dickinson D, Ragland JD, Gold JM, Gur RC. General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol Psychiatry. 2008;64:823\u20137.","journal-title":"Biol Psychiatry"},{"key":"72_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1017\/S0033291708004558","volume":"39","author":"NF Forbes","year":"2009","unstructured":"Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: a meta-analysis. Psychol Med. 2009;39:889\u2013905.","journal-title":"Psychol Med"},{"key":"72_CR28","first-page":"290","volume":"26","author":"C Lejuez","year":"2003","unstructured":"Lejuez C, Kahler CW, Brown RA. A modified computer version of the Paced Auditory Serial Addition Task (PASAT) as a laboratory based stressor. Behav Ther. 2003;26:290\u20133.","journal-title":"Behav Ther"},{"key":"72_CR29","unstructured":"Strong D, Lejuez C, Daughters S, Marinello M, Kahler C, Brown R. The computerized mirror tracing task version 1. 2003. Unpublished manual."},{"key":"72_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.psychres.2014.07.026","volume":"220","author":"KL Nugent","year":"2014","unstructured":"Nugent KL, Chiappelli J, Rowland LM, Daughters SB, Hong LE. Distress intolerance and clinical functioning in persons with schizophrenia. Psychiatry Res. 2014;220:31\u20136.","journal-title":"Psychiatry Res"},{"key":"72_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00702-011-0706-6","volume":"119","author":"SK Olsson","year":"2012","unstructured":"Olsson SK, Larsson MK, Erhardt S. Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice. J Neural Transm. 2012;119:155\u201363.","journal-title":"J Neural Transm"},{"key":"72_CR32","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1111\/j.1460-9568.2012.08064.x","volume":"35","author":"A Pocivavsek","year":"2012","unstructured":"Pocivavsek A, Wu HQ, Elmer GI, Bruno JP, Schwarcz R. Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci. 2012;35:1605\u201312.","journal-title":"Eur J Neurosci"},{"key":"72_CR33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/jmri.22638","volume":"34","author":"SA Wijtenburg","year":"2011","unstructured":"Wijtenburg SA, Knight-Scott J. Very short echo time improves the precision of glutamate detection at 3T in 1H magnetic resonance spectroscopy. J Magn Reson Imaging. 2011;34:645\u201352.","journal-title":"J Magn Reson Imaging"},{"key":"72_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mrm.24959","volume":"72","author":"SA Wijtenburg","year":"2014","unstructured":"Wijtenburg SA, Gaston FE, Spieker EA, Korenic SA, Kochunov P, Hong LE, et al. Reproducibility of phase rotation STEAM at 3T: focus on glutathione. Magn Reson Med. 2014;72:603\u20139.","journal-title":"Magn Reson Med"},{"key":"72_CR35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jmr.2007.01.005","volume":"185","author":"BJ Soher","year":"2007","unstructured":"Soher BJ, Young K, Bernstein A, Aygula Z, Maudsley AA. GAVA: spectral simulation for in vivo MRS applications. J Magn Reson. 2007;185:291\u20139.","journal-title":"J Magn Reson"},{"key":"72_CR36","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mrm.1910300604","volume":"30","author":"SW Provencher","year":"1993","unstructured":"Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672\u20139.","journal-title":"Magn Reson Med"},{"key":"72_CR37","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/mrm.20901","volume":"55","author":"C Gasparovic","year":"2006","unstructured":"Gasparovic C, Song T, Devier D, Bockholt HJ, Caprihan A, Mullins PG, et al. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med. 2006;55:1219\u201326.","journal-title":"Magn Reson Med"},{"key":"72_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jamapsychiatry.2015.2680","volume":"73","author":"LM Rowland","year":"2016","unstructured":"Rowland LM, Summerfelt A, Wijtenburg SA, Du X, Chiappelli JJ, Krishna N, et al. Frontal glutamate and \u03b3-aminobutyric acid levels and their associations with mismatch negativity and digit sequencing task performance in schizophrenia. JAMA Psychiatry. 2016;73:166\u201374.","journal-title":"JAMA Psychiatry"},{"key":"72_CR39","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/npp.2016.172","volume":"42","author":"SA Wijtenburg","year":"2017","unstructured":"Wijtenburg SA, Wright SN, Korenic SA, Gaston FE, Ndubuizu N, Chiappelli J, et al. Altered glutamate and regional cerebral blood flow levels in schizophrenia: a 1H-MRS and pCASL study. Neuropsychopharmacology. 2017;42:562\u201371.","journal-title":"Neuropsychopharmacology"},{"key":"72_CR40","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S0306-4530(02)00108-7","volume":"28","author":"JC Pruessner","year":"2003","unstructured":"Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology. 2003;28:916\u201331.","journal-title":"Psychoneuroendocrinology"},{"key":"72_CR41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbi.2017.01.013","volume":"62","author":"AL Marsland","year":"2017","unstructured":"Marsland AL, Kuan DC, Sheu LK, Krajina K, Kraynak TE, Manuck SB, et al. Systemic inflammation and resting state connectivity of the default mode network. Brain Behav Immun. 2017;62:162\u201370.","journal-title":"Brain Behav Immun"},{"key":"72_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.neuron.2009.09.039","volume":"64","author":"M Rosas-Ballina","year":"2009","unstructured":"Rosas-Ballina M, Tracey KJ. The neurology of the immune system: neural reflexes regulate immunity. Neuron. 2009;64:28\u201332.","journal-title":"Neuron"},{"key":"72_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1042\/bj2290499","volume":"229","author":"M Salter","year":"1985","unstructured":"Salter M, Pogson CI. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J. 1985;229:499\u2013504.","journal-title":"Biochem J"},{"key":"72_CR44","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0165-5728(01)00489-1","volume":"123","author":"WB Malarkey","year":"2002","unstructured":"Malarkey WB, Wang J, Cheney C, Glaser R, Nagaraja H. Human lymphocyte growth hormone stimulates interferon gamma production and is inhibited by cortisol and norepinephrine. J Neuroimmunol. 2002;123:180\u20137.","journal-title":"J Neuroimmunol"},{"key":"72_CR45","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/jir.2005.25.384","volume":"25","author":"M Wahle","year":"2005","unstructured":"Wahle M, Neumann RP, Moritz F, Krause A, Buttgereit F, Baerwald CG. Beta2-adrenergic receptors mediate the differential effects of catecholamines on cytokine production of PBMC. J Interferon Cytokine Res. 2005;25:384\u201394.","journal-title":"J Interferon Cytokine Res"},{"key":"72_CR46","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.bbagen.2016.07.002","volume":"1860","author":"PB Larkin","year":"2016","unstructured":"Larkin PB, Sathyasaikumar KV, Notarangelo FM, Funakoshi H, Nakamura T, Schwarcz R, et al. Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice. Biochim Biophys Acta. 2016;1860:2345\u201354.","journal-title":"Biochim Biophys Acta"},{"key":"72_CR47","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.neuroscience.2010.05.052","volume":"169","author":"A Konradsson-Geuken","year":"2010","unstructured":"Konradsson-Geuken A, Wu HQ, Gash CR, Alexander KS, Campbell A, Sozeri Y, et al. Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience. 2010;169:1848\u201359.","journal-title":"Neuroscience"},{"key":"72_CR48","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0014-2999(92)90626-F","volume":"213","author":"HQ Wu","year":"1992","unstructured":"Wu HQ, Ungerstedt U, Schwarcz R. Regulation of kynurenic acid synthesis studied by microdialysis in the dorsal hippocampus of unanesthetized rats. Eur J Pharmacol. 1992;213:375\u201380.","journal-title":"Eur J Pharmacol"},{"key":"72_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s12031-009-9235-2","volume":"40","author":"HQ Wu","year":"2010","unstructured":"Wu HQ, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci. 2010;40:204\u201310.","journal-title":"J Mol Neurosci"},{"key":"72_CR50","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/npp.2010.39","volume":"35","author":"MC Potter","year":"2010","unstructured":"Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, et al. Reduction of endogenous kynurenate formation enhances extracellular glutamate, hippocampal plasticity and cognitive behavior. Neuropsychopharmacology. 2010;35:1734\u201342.","journal-title":"Neuropsychopharmacology"},{"key":"72_CR51","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/(SICI)1097-4547(19971101)50:3<457::AID-JNR12>3.0.CO;2-3","volume":"50","author":"P Guidetti","year":"1997","unstructured":"Guidetti P, Okuno E, Schwarcz R. Characterization of rat brain kynurenine aminotransferases I and II. J Neurosci Res. 1997;50:457\u201365.","journal-title":"J Neurosci Res"},{"key":"72_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neuropharm.2017.04.023","volume":"121","author":"DM Bortz","year":"2017","unstructured":"Bortz DM, Wu HQ, Schwarcz R, Bruno JP. Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex. Neuropharmacology. 2017;121:69\u201378.","journal-title":"Neuropharmacology"},{"key":"72_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neuropharm.2014.03.004","volume":"82","author":"A Koshy Cherian","year":"2014","unstructured":"Koshy Cherian A, Gritton H, Johnson DE, Young D, Kozak R, Sarter M. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology. 2014;82:41\u20138.","journal-title":"Neuropharmacology"},{"key":"72_CR54","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/npp.2016.66","volume":"41","author":"J Chiappelli","year":"2016","unstructured":"Chiappelli J, Postolache TT, Kochunov P, Rowland LM, Wijtenburg SA, Shukla DK, et al. Tryptophan metabolism and white matter integrity in schizophrenia. Neuropsychopharmacology. 2016;41:2587\u201395.","journal-title":"Neuropsychopharmacology"},{"key":"72_CR55","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","volume":"56","author":"S Fukui","year":"1991","unstructured":"Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007\u201317.","journal-title":"J Neurochem"},{"key":"72_CR56","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1073\/pnas.1115628109","volume":"109","author":"LE Falkenberg","year":"2012","unstructured":"Falkenberg LE, Westerhausen R, Specht K, Hugdahl K. Resting-state glutamate level in the anterior cingulate predicts blood-oxygen level-dependent response to cognitive control. Proc Natl Acad Sci USA. 2012;109:5069\u201373.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0072-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0072-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0072-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:57Z","timestamp":1684616577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0072-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0072-2","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"3 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Hong has received or plans to receive research funding or consulting fees from Mitsubishi, Your Energy Systems LLC, Neuralstem, Taisho Pharmaceutical, Sound Pharma, Heptares, Pfizer, and Takeda. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}